| Literature DB >> 33901247 |
Renata Kielnar1, Anna Mika2, Dorota Bylina3, Jarosław Sołtan4, Artur Stolarczyk5, Błażej Pruszczyński6, Henryk Racheniuk7, Jan Szczegielniak7, Aleksandra Królikowka8, Łukasz Oleksy5,9.
Abstract
BACKGROUND: Coexistence of temporomandibular joint discomfort along with cervical spine disorders is quite common, and is associated with many limitations and adverse symptoms for the patient. Both diagnostics and treatment of these ailments are difficult, and in many cases, the effects of therapy are not satisfactory. This study assessed the impact of a 3-week neck-only rehabilitation programme without direct intervention in the craniofacial area on the bioelectric activity of both the cervical spine and muscles in the craniofacial area among patients with idiopathic neck pain who do not report TMJ pain.Entities:
Mesh:
Year: 2021 PMID: 33901247 PMCID: PMC8075221 DOI: 10.1371/journal.pone.0250746
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Patients’ characteristics.
| Experimental Group | Control Group | |
|---|---|---|
| Number of subjects (n) | 25 | 35 |
| Sex | 21 women, 4 men | 29 women, 6 men |
| Age (years) | 27–57 (38.5±8.52) | 27–47 (35.1±5.65) |
| Body mass (kg) | 62±11.9 | 64.3±14.1 |
| Body height (cm) | 164.6±6.3 | 166.2±5.3 |
| Ethnicity | Caucasian | Caucasian |
Fig 1Consort flow diagram.
Fig 2Flow diagram of the study procedure.
Changes in muscles bioelectrical activity during Cervical Spine Posture test at Baseline/Postural Evaluation (10-second rest) phase.
| Outcome Measure | Experimental Group | p# | ES# | Control Group | p# | ES# | p* | p** | |
|---|---|---|---|---|---|---|---|---|---|
| SCM L (μV) | Baseline | 7.8±5.1 (5.6–9.9) | 3.7±1.9 (3.0–4.3) | n.s. | 0.05 | n.s. | |||
| Post | 5.5±3.1 (4.2–6.7) | 3.6±1.5 (3.0–4.1) | n.s. | ||||||
| SCM R (μV) | Baseline | 7.2±4.7 (5.2–9.1) | 4.2±2.2 (3.4–4.9) | n.s. | 0.05 | n.s. | |||
| Post | 5.2±3.0 (3.9–6.4) | 4.3±1.3 (3.8–4.7) | n.s. | ||||||
| TA L (μV) | Baseline | 7.8±5.8 (5.4–10.1) | n.s. | 0.07 | 6.5±1.8 (5.8–7.1) | n.s. | 0.04 | n.s. | n.s. |
| Post | 7.4±4.3 (5.6–9.1) | 6.4±2.8 (5.4–7.3) | n.s. | ||||||
| TA R (μV) | Baseline | 9.0±7.2 (6.0–11.9) | n.s. | 0.40 | 6.9±2.0 (6.2–7.5) | n.s. | 0.05 | n.s. | n.s. |
| Post | 6.8±2.4 (5.8–7.7) | 6.7±2.7 (5.7–7.6) | n.s. | ||||||
| MASS L (μV) | Baseline | 4.1±1.9 (3.3–4.8) | n.s. | 0.07 | 3.5±1.6 (2.9–4.0) | n.s. | 0.04 | n.s. | n.s. |
| Post | 4.3±3.3 (2.9–5.6) | 3.5±1.7 (2.9–4.0) | n.s. | ||||||
| MASS R (μV) | Baseline | 3.5±2.6 (2.4–4.5) | n.s. | 0.45 | 3.3±1.4 (2.8–3.7) | n.s. | 0.04 | n.s. | n.s. |
| Post | 2.6±1.1 (2.1–3.0) | 3.6±1.9 (2.9–4.2) | n.s. | ||||||
| CERV L (μV) | Baseline | 5.1±2.5 (4.0–6.1) | n.s. | 0.16 | 4.3±1.3 (3.8–4.7) | n.s. | 0.02 | n.s. | n.s. |
| Post | 5.6±3.6 (4.1–7.0) | 4.4±1.3 (3.9–4.8) | n.s. | ||||||
| CERV R (μV) | Baseline | 4.6±1.7 (3.8–5.3) | n.s. | 0.05 | 3.5±1.3 (3.0–3.9) | n.s. | 0.04 | n.s. | n.s. |
| Post | 4.7±2.0 (3.8–5.5) | 3.6±1.3 (3.1–4.0) | n.s. |
p#—p value between baseline and post- therapy within each group (time main effect).
p*—p value between study groups (group main effect).
ES#–effect size (Cohen d) within each group.
p**–p value of main effects interaction.
Values are expressed as Mean ± SD (95% Confidence Interval).
Changes in muscles bioelectrical activity during Functional Clench phase.
| Outcome Measure | Experimental Group | p# | ES# | Control Group | p# | ES# | p* | p** | |
|---|---|---|---|---|---|---|---|---|---|
| SCM L (μV) | Baseline | 7.4±4.3 (5.6–9.1) | 5.1±2.4 (4.2–5.9) | n.s. | 0.04 | n.s. | |||
| Post | 4.0±2.9 (2.8–5.1) | 5.0±2.2 (4.2–5.7) | n.s. | ||||||
| SCM R (μV) | Baseline | 6.9±2.8 (5.7–8.0) | 5.7±2.2 (4.9–6.4) | n.s. | 0.09 | n.s. | n.s. | ||
| Post | 4.7±2.9 (5.5–5.8) | 5.5±1.8 (4.8–6.1) | n.s. | ||||||
| TA L (μV) | Baseline | 29.1±7.6 (25.9–32.2) | 28.9±8.8 (25.8–31.9) | n.s. | 0.09 | n.s. | n.s. | ||
| Post | 22.1±6.7 (19.3–24.8) | 28.1±7.8 (25.4–30.7) | |||||||
| TA R (μV) | Baseline | 28.4±10.4 (24.1–32.6) | 24.6±9.1 (21.4–27.7) | n.s. | 0.01 | n.s. | n.s. | ||
| Post | 23.2±8.1 (19.8–26.5) | 24.5±7.9 (21.7–27.2) | n.s. | ||||||
| MASS L (μV) | Baseline | 27.0±7.8 (23.7–30.2) | n.s. | 0.13 | 26.4±8.5 (23.4–29.3) | n.s. | 0.03 | n.s. | n.s. |
| Post | 25.8±9.3 (21.9–29.6) | 26.1±7.5 (23.5–28.6) | n.s. | ||||||
| MASS R (μV) | Baseline | 24.4±9.1 (20.6–28.1) | 24.1±6.2 (21.9–26.2) | n.s. | 0.18 | n.s. | n.s. | ||
| Post | 21.7±7.6 (18.5–24.8) | 25.1±4.7 (23.4–26.7) | |||||||
| CERV L (μV) | Baseline | 5.1±2.9 (3.9–6.2) | n.s. | 0.34 | 4.9±1.9 (4.2–5.5) | n.s. | 0.10 | n.s. | n.s. |
| Post | 5.9±1.6 (5.2–6.5) | 4.7±2.0 (4.0–5.3) | n.s. | ||||||
| CERV R (μV) | Baseline | 4.4±1.7 (3.6–5.1) | n.s. | 0.29 | 4.1±1.9 (3.4–4.7) | n.s. | 0.11 | n.s. | n.s. |
| Post | 5.0±2.3 (5.6–2.3) | 4.3±1.7 (3.7–4.8) | n.s. |
p#—p value between baseline and post- therapy within each group (time main effect).
p*—p value between study groups (group main effect).
ES#–effect size (Cohen d) within each group.
p**–p value of main effects interaction.
Values are expressed as Mean ± SD (95% Confidence Interval).
Changes in muscles bioelectrical activity during Functional Clench with Control phase.
| Outcome Measure | Experimental Group | p# | ES# | Control Group | p# | ES# | p* | p** | |
|---|---|---|---|---|---|---|---|---|---|
| SCM L (μV) | Baseline | 7.9±4.1 (6.2–9.5) | n.s. | 0.37 | 7.1±3.9 (5.7–8.4) | n.s. | 0.05 | n.s. | n.s. |
| Post | 6.6±2.6 (5.5–7.6) | 6.9±3.4 (5.7–8.0) | n.s. | ||||||
| SCM R (μV) | Baseline | 7.6±3.6 (6.1–9.0) | n.s. | 0.14 | 7.3±3.2 (6.2–8.3) | n.s. | 0.02 | n.s. | n.s. |
| Post | 7.1±3.1 (5.8–8.3) | 7.2±3.6 (5.9–8.4) | n.s. | ||||||
| TA L (μV) | Baseline | 27.4±8.6 (23.8–30.9) | 23.7±6.8 (21.3–26.0) | n.s. | 0.09 | n.s. | |||
| Post | 23.5±6.4 (20.8–26.1) | 23.1±5.8 (21.1–25.0) | n.s. | ||||||
| TA R (μV) | Baseline | 25.9±9.6 (21.9–29.8) | n.s. | 0.18 | 24.1±7.0 (21.6–26.5) | n.s. | 0.07 | n.s. | n.s. |
| Post | 24.2±8.6 (20.6–27.7) | 23.6±6.9 (21.2–25.9) | n.s. | ||||||
| MASS L (μV) | Baseline | 29.5±6.8 (26.6–32.3) | 27.2±7.5 (24.6–29,7) | n.s. | 0.01 | n.s. | n.s. | ||
| Post | 24.5±9.6 (20.5–28.4) | 27.3±8.5 (24.3–30.2) | n.s. | ||||||
| MASS R (μV) | Baseline | 31.7±7.2 (28.7–34.6) | 29.8±6.2 (27.6–31.9) | n.s. | 0.24 | n.s. | n.s. | ||
| Post | 24.6±7.5 (21.5–27.6) | 28.3±6.1 (26.2–30.3) | |||||||
| CERV L (μV) | Baseline | 4.2±2.6 (3.1–5.2) | n.s. | 0.22 | 4.9±1.9 (4.2–5.5) | n.s. | 0.35 | n.s. | n.s. |
| Post | 4.8±2.7 (3.6–5.9) | 4.2±2.0 (3.5–4.8) | n.s. | ||||||
| CERV R (μV) | Baseline | 4.5±2.1 (3.6–5.3) | n.s. | 0.16 | 4.3±1.7 (3.7–4.8) | n.s. | 0.11 | n.s. | n.s. |
| Post | 4.9±2.7 (3.7–6.0) | 4.1±1.8 (3.4–4.7) | n.s. |
p#—p value between baseline and post- therapy within each group (time main effect).
p*—p value between study groups (group main effect).
ES#–effect size (Cohen d) within each group.
p**–p value of main effects interaction.
Values are expressed as Mean ± SD (95% Confidence Interval).
Changes in muscles bioelectrical activity during Clinical Sequence Assessments for the Cervical region at Cervical Flexion and Return to neutral phase.
| Outcome Measure | Experimental Group | p# | ES# | Control Group | p# | ES# | p* | p** | |
|---|---|---|---|---|---|---|---|---|---|
| SCM L (μV) flexion | Baseline | 25.9±10.1 (21.7–30.0) | 18.9±10.9 (15.1–22.6) | n.s. | 0.02 | n.s. | n.s. | ||
| Post | 17.2±8.6 (13.6–20.7) | 18.7±8.8 (15.6–21.7) | n.s. | ||||||
| SCM R (μV) flexion | Baseline | 25.1±8.6 (21.5–28.6) | 20.4±9.2 (17.2–23.5) | n.s. | 0.09 | n.s. | n.s. | ||
| Post | 16.8±7.1 (13.8–19.7) | 19.9±7.6 (17.2–22.5) | n.s. | ||||||
| UP TRA L (μV) flexion | Baseline | 15.3±8.2 (11.9–18.6) | 12.7±4.8 (11.0–14.3) | n.s. | 0.01 | n.s. | |||
| Post | 20.0±10.4 (15.7–24.2) | 12.7±4.6 (11.1–14.2) | n.s. | ||||||
| UP TRA R (μV) flexion | Baseline | 11.1±7.6 (7.9–14.2) | 11.5±3.0 (10.4–12.5) | n.s. | 0.30 | n.s. | n.s. | ||
| Post | 15.7±8.6 (12.1–19.2) | 10.6±2.9 (9.6–11.5) | n.s. | ||||||
| CERV L (μV) flexion | Baseline | 11.6±7.1 (3.6–14.5) | n.s. | 0.06 | 11.3±4.5 (9.7–12.8) | n.s. | 0.12 | n.s. | n.s. |
| Post | 11.1±7.6 (7.9–14.2) | 10.8±3.5 (9.5–12.0) | n.s. | ||||||
| CERV R (μV) flexion | Baseline | 10.9±6.2 (8.3–13.4) | n.s. | 0.14 | 10.4±4.2 (8.9–11.8) | n.s. | 0.07 | n.s. | n.s. |
| Post | 9.9±7.5 (6.8–12.9) | 10.7±4.1 (9.2–12.1) | |||||||
| SCM L (μV) return | Baseline | 19.8±8.3 (16.3–23.2) | n.s. | 0.38 | 16.2±5.9 (14.1–18.2) | n.s. | 0.08 | n.s. | |
| Post | 17.0±6.3 (14.3–19.6) | 15.7±6.0 (13.6–17.7) | n.s. | ||||||
| SCM R (μV) return | Baseline | 19.5±7.5 (16.4–22.5) | 16.4±4.7 (14.7–18.0) | n.s. | 0.18 | n.s. | |||
| Post | 14.4±6.7 (11.6–17.1) | 15.5±4.8 (13.8–17.1) | n.s. | ||||||
| UP TRA L (μV) return | Baseline | 14.2±5.4 (11.9–19.4) | n.s. | 0.48 | 12.7±3.8 (11.3–14.0) | n.s. | 0.02 | n.s. | n.s. |
| Post | 16.8±5.3 (14.6–18.9) | 12.6±4.8 (10.9–14.2) | n.s. | ||||||
| UP TRA R (μV) return | Baseline | 15.8±8.5 (12.2–19.3) | n.s. | 0.47 | 11.3±3.3 (10.1–12.4) | n.s. | 0.35 | n.s. | |
| Post | 12.5±4.9 (10.4–14.5) | 12.4±2.8 (11.4–13.3) | n.s. | ||||||
| CERV L (μV) return | Baseline | 14.9±6.8 (12.0–17.7) | n.s. | 0.07 | 13.5±6.1 (11.4–15.5) | n.s. | 0.05 | n.s. | n.s. |
| Post | 14.4±6.2 (11.8–16.9) | 13.2±4.9 (11.5–14.8) | n.s. | ||||||
| CERV R (μV) return | Baseline | 14.4±4.8 (12.4–16.3) | n.s. | 0.06 | 13.6±4.8 (11.9–15.2) | n.s. | 0.25 | n.s. | n.s. |
| Post | 14.7±3.9 (13.0–16.3) | 12.5±3.6 (11.2–13.7) | n.s. |
p#—p value between baseline and post- therapy within each group (time main effect).
p*—p value between study groups (group main effect).
ES#–effect size (Cohen d) within each group.
p**–p value of main effects interaction.
Values are expressed as Mean ± SD (95% Confidence Interval).
Changes in muscles bioelectrical activity during Clinical Sequence Assessments for TMJ region at Prolonged Clench with Control—Fatigue Analysis phase.
| Outcome Measure | Experimental Group | p# | ES# | Control Group | p# | ES# | p* | p** | |
|---|---|---|---|---|---|---|---|---|---|
| SCM L (μV) | Baseline | 84.0±53.1 (62.0–105.9) | 93.5±41.9 (79.1–107.8) | n.s. | 0.21 | n.s. | n.s. | ||
| Post | 36.7±17.3 (29.5–43.8) | 85.1±36.2 (72.6–97.5) | |||||||
| SCM R (μV) | Baseline | 88.4±43.7 (70.3–106.4) | 89.6±32.7 (78.3–100.8) | n.s. | 0.07 | n.s. | n.s. | ||
| Post | 33.5±15.0 (27.3–39.6) | 86.8±39.6 (73.1–100.4) | |||||||
| TA L (μV) | Baseline | 46.6±21.8 (37.6–55.5) | 44.5±22.8 (36.6–52.3) | n.s. | 0.04 | n.s. | |||
| Post | 13.7±8.3 (10.2–17.1) | 45.5±17.8 (39.3–51.6) | |||||||
| TA R (μV) | Baseline | 54.2±23.2 (44.6–63.7) | 38.6±16.4 (32.9–44.2) | n.s. | 0.08 | n.s. | n.s. | ||
| Post | 16.4±9.4 (12.5–20.2) | 37.2±16.4 (31.5–42.8) | |||||||
| MASS L (μV) | Baseline | 44.9±19.7 (36.7–53.0) | 43.1±12.7 (38.7–47.4) | n.s. | 0.35 | n.s. | n.s. | ||
| Post | 20.6±8.7 (17.0–24.1) | 48.3±16.6 (42.5–54.0) | |||||||
| MASS R (μV) | Baseline | 57.2±28.3 (45.5–68.8) | 44.8±22.2 (37.1–52.4) | n.s. | 0.06 | n.s. | n.s. | ||
| Post | 24.6±10.2 (20.3–28.8) | 46.2±18.7 (39.7–52.6) |
p#—p value between baseline and post- therapy within each group (time main effect).
p*—p value between study groups (group main effect).
ES#–effect size (Cohen d) within each group.
p**–p value of main effects interaction.
Values are expressed as Mean ± SD (95% Confidence Interval).